Suppressed humoral immune response to PSA in CaP patients

Amnon Zisman, Einat Zisman, Edna Mozes, Sergey Velikanov, Yoram I. Seigel, Arie Lindner*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Cancer has been reported to correlate with depressed immune responses. BPH patients were shown to have high titers of circulating anti-PSA antibodies. Our goal is to find out whether the humoral immune response to PSA is impaired in prostate cancer (CaP) patients. Methods: Titers of IgG Ab to PSA were determined in the sera of 15 CaP patients, 36 BPH patients and 20 controls by enzyme-linked immunosorbent assay (ELISA). Results: The mean titers of anti-PSA Ab as well as Ab to a recall antigen (Tetanus toxoid) in the CaP group were significantly lower than in the BPH group (0.29 ± 0.12 and 0.68 ± 0.22 versus 0.51 ± 0.35 and 0.87 ± 0.25, respectively). Yet, the anti-PSA Ab titers in the CaP patients were significantly higher than in the control group. Conclusion: These results imply that specific antibody responses are suppressed in CaP patients.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalProstate Journal
Issue number1
StatePublished - 1999


Dive into the research topics of 'Suppressed humoral immune response to PSA in CaP patients'. Together they form a unique fingerprint.

Cite this